Efectividad del tratamiento del linfoma no Hodgkin con R-CHOP, Instituto Regional de Enfermedades Neoplásicas - Trujillo
No Thumbnail Available
Date
2024
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
La investigación tuvo como objetivo determinar la efectividad del esquema R-CHOP en el tratamiento de linfoma no Hodgkin en el Instituto Regional de Enfermedades Neoplásicas, Trujillo-Perú. Se incluyeron las historias clínicas de 127 pacientes con diagnóstico de linfoma no Hodgkin que solo recibieron tratamiento de R-CHOP del 2017 al 2023. Se tomaron en cuenta: número de historia clínica, sexo, edad, estadio clínico del cáncer, fechas de infusión del protocolo, número de protocolos programados e infundidos, valor del factor CD20, número de recaídas o remisión completa, años de supervivencia con la enfermedad, uso de filgrastim dentro del esquema y anafilaxias. El 52,76 % de pacientes fueron del sexo femenino, la edad promedio de 60,22 años y el grupo etario mayoritario de 60 a 70 años, mientras que el número de ciclos recibidos promedio fue de 4,5. Los pacientes con linfoma no Hodgkin infundidos con R-CHOP presentaron remisión al 100 % en el estadio I; 93,33 % en el estadio IIA; 52,94 % en el estadio IIB; 85,19 % en el estadio IIIA; 69,23 % en el estadio IIIB y 42,86 % en el estadio IV, siendo la remisión promedio de 76,38 %. La supervivencia libre de progresión (SLP) fue de 3,44 años y el porcentaje de supervivencia global a 4 años fue de 93,5 %. Se concluye que la efectividad de R-CHOP en pacientes con linfoma no Hodgkin varía con los parámetros de SLP y remisión de acuerdo a cada estadio clínico del cáncer.
The objective of the research was to determine the effectiveness of the R-CHOP scheme in the treatment of non-Hodgkin lymphoma at the Regional Institute of Neoplastic Diseases, Trujillo-Peru. The medical records of 127 patients with a diagnosis of non-Hodgkin lymphoma who only received R-CHOP treatment from 2017 to 2023 were included. The following were taken into account: medical record number, sex, age, clinical stage of cancer, dates of infusion of the protocol, number of programmed and infused protocols, CD20 factor value, number of relapses or complete remission, years of survival with the disease, use of filgrastim within the regimen and anaphylaxis. 52.76% of patients were female, the average age was 60.22 years and the majority age group was 60 to 70 years, while the average number of cycles received was 4,5. Non-Hodgkin lymphoma patients infused with R-CHOP had 100% remission in stage I; 93.33% in stage IIA; 52.94% in stage IIB; 85.19% in stage IIIA; 69.23% in stage IIIB and 42.86% in stage IV, with the average remission being 76.38%. Progression-free survival (PFS) was 3.44 years and the 4-year overall survival rate was 93,5%. It is concluded that the effectiveness of R-CHOP in patients with non-Hodgkin lymphoma varies with the PFS and remission parameters according to each clinical stage of the cancer.
The objective of the research was to determine the effectiveness of the R-CHOP scheme in the treatment of non-Hodgkin lymphoma at the Regional Institute of Neoplastic Diseases, Trujillo-Peru. The medical records of 127 patients with a diagnosis of non-Hodgkin lymphoma who only received R-CHOP treatment from 2017 to 2023 were included. The following were taken into account: medical record number, sex, age, clinical stage of cancer, dates of infusion of the protocol, number of programmed and infused protocols, CD20 factor value, number of relapses or complete remission, years of survival with the disease, use of filgrastim within the regimen and anaphylaxis. 52.76% of patients were female, the average age was 60.22 years and the majority age group was 60 to 70 years, while the average number of cycles received was 4,5. Non-Hodgkin lymphoma patients infused with R-CHOP had 100% remission in stage I; 93.33% in stage IIA; 52.94% in stage IIB; 85.19% in stage IIIA; 69.23% in stage IIIB and 42.86% in stage IV, with the average remission being 76.38%. Progression-free survival (PFS) was 3.44 years and the 4-year overall survival rate was 93,5%. It is concluded that the effectiveness of R-CHOP in patients with non-Hodgkin lymphoma varies with the PFS and remission parameters according to each clinical stage of the cancer.
Description
Keywords
HUMANITIES and RELIGION::History and philosophy subjects::History subjects::History